Key Dates

Related Announcements

PAR-18-657 Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 Clinical Trial Optional)

Issued by

National Eye Institute (NEI)

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

National Institute on Drug Abuse (NIDA)

National Institute of Environmental Health Sciences (NIEHS)

Purpose

The NIH Countermeasures Against Chemical Threats (CounterACT) program supports research and development of therapeutics that can reduce mortality and morbidity in the event of the release of chemical threat agents. An important component of the CounterACT research network are the U54 Research Centers of Excellence. The U54 Centers are designed to support three or more projects and scientific cores having a unifying well-defined goal or problem area of research that synergistically produce rigorous interdisciplinary research of the highest quality. There is the expectation that support of interrelated projects and collaborating investigators would yield results beyond those achievable if each project were pursued separately without formal interaction among the participating investigators.

For more information on the CounterACT Program, please visit our website. To view a list of currently funded projects, please visit our webpage, CounterACT Research Network and Funded Investigators.

The NIH CounterACT program is issuing this NOSI to provide the chemical threat agents that will be supported in grant applications for the September 9, 2020 receipt date for PAR-18-657 U54 Centers of Excellence. The only chemical agents that will be supported in the U54 program are:

• Blood/Metabolic Agents: hydrogen cyanide, potassium cyanide and sodium cyanide
• Organophosphorus (OP) Chemical Warfare Agents and Pesticides
• Opioids: carfentanil, fentanyl and related analogs, see NOT-NS-18-019
• Pulmonary Agents: chlorine and phosgene
• Vesicants: sulfur mustard and lewisite

Applicants are strongly encouraged to contact the CounterACT Program Staff listed in the parent funding opportunity announcement (PAR-18-657) to determine if their proposed threat agent(s) is of interest to the NIH CounterACT program. Applications that propose research on chemical threats that are not listed above will not be considered for funding. If research related to opioid threats is being proposed, see NOT-NS-18-019 for a description of research supported by the NIH CounterACT program.

Application and Submission Information

Submit applications for this initiative using the following funding opportunity announcement through the expiration date of this notice.

• PAR-18-657 - Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 Clinical Trial Optional)
• This notice applies to the September 9, 2020 due date of PAR-18-657.

All instructions in the SF424 (R&R) Application Guide and the funding opportunity announcement used for submissionmust be followed, with the following additions

• For funding consideration, applicants must include NOT-NS-20-031 (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.

Inquiries